Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon

Rheumatology

Volumn 40, Issue 2, 2001, Pages 140-146

  Istok, R ^a   Czirjak L ^b   Lukac J ^a   Stancikova M ^a   Rovensky, J ^a  

^a NATIONAL INSTITUTE OF RHEUMATIC DISEASES   (Slovakia)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Deoxypyridinoline; Fibrosis; Pyridinoline; Raynaud's phenomenon; Scleroderma; Systemic sclerosis

Indexed keywords

COLLAGEN; DEOXYPYRIDINOLINE; PYRIDINOLINE;

ADULT; ARTICLE; BONE; CHEMICAL ANALYSIS; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS LINKING; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FIBROSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SCORING SYSTEM; SKIN MANIFESTATION; SOFT TISSUE; SYSTEMIC SCLEROSIS; URINALYSIS; URINE LEVEL;

EID: 0035090612     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/40.2.140     Document Type: Article

References (29)

1. Organ involvement: Skin
2. Serum and urinary aminoterminal type III procollagen peptide in progressive systemic sclerosis: Relationship to sclerodermal involvement, serum hyaluronan and urinary collagen metabolites
3. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis
4. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: Relationship to disease activity and duration
5. Collagenase in scleroderma
6. Decreased collagenase expression in cultured systemic sclerosis fibroblasts
7. Modulation of interstitial collagenase in scleroderma and normal fibroblasts
8. Evidence for bone resorption in systemic sclerosis
9. Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma
10. Circulating type I collagen degradation products: A new serum marker for clinical severity in patients with scleroderma?
11. Cross-linking of collagen. Isolation, structural characterisation and glycosylation of pyridinoline
12. Quantitation of hydroxypyridinium cross-link of collagen by high performance liquid chromatography
13. Urinary pyridinium cross-links of collagen. Specific markers of bone resorption in metabolic bone disease
14. Predictors of survival in 171 patients with systemic sclerosis (scleroderma)
15. Survival analysis of 118 patients with systemic sclerosis
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
17. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
18. A modified scleroderma skin scoring method
19. Raynaud's phenomenon: A proposal for classification
20. Wide-field capillary microscopy
21. Determination of hydroxylysylpyridinoline in tissues and urine by high-performance liquid chromatography
22. Localisation of collagen mRNA in normal and scleroderma skin by in situ hybridization
23. Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis
24. Increased expression of lysyl oxidase in skin with scleroderma
25. Altered x-ray diffraction pattern is accompanied by a change in the node of cross-link formation in lipodermatosclerosis
26. Cross-link of collagen in hypertrophic scar
27. Pyridinoline in fibrotised tissues of patients with systemic sclerosis
28. Mature type of skin collagen cross-link, histidinohydroxylysinorleucine, is significantly increased in the skin of systemic sclerosis patients
29. Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma